Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.61 USD | 0.00% | +10.06% | +572.25% |
May. 14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
May. 02 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 139.7 | 22.12 | 22.78 | 197.2 | - | - |
Enterprise Value (EV) 1 | 139.7 | 22.12 | 22.78 | 197.2 | 197.2 | 197.2 |
P/E ratio | -2.28 x | -0.23 x | -0.4 x | -3.89 x | -3.92 x | -3.48 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -4,360,314 x | - | - | - | - | - |
EV / FCF | -4.63 x | -0.26 x | -0.41 x | -4.67 x | -3.14 x | -2.21 x |
FCF Yield | -21.6% | -387% | -247% | -21.4% | -31.9% | -45.3% |
Price to Book | 0.99 x | - | - | - | - | - |
Nbr of stocks (in thousands) | 23,198 | 23,285 | 42,415 | 54,638 | - | - |
Reference price 2 | 6.020 | 0.9500 | 0.5370 | 3.610 | 3.610 | 3.610 |
Announcement Date | 3/3/22 | 3/9/23 | 3/6/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | -32.03 | - | - | - | - | - |
EBIT 1 | - | -32.05 | -94.55 | -40.34 | -44.57 | -56.11 | -75.18 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -32.04 | -95.06 | -45.67 | -46.51 | -60.12 | -78.18 |
Net income 1 | -17.26 | -32.04 | -95.08 | -45.7 | -48.09 | -60.9 | -78.03 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -21.80 | -2.640 | -4.090 | -1.340 | -0.9283 | -0.9217 | -1.038 |
Free Cash Flow 1 | - | -30.17 | -85.57 | -56.18 | -42.23 | -62.83 | -89.37 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 6/4/21 | 3/3/22 | 3/9/23 | 3/6/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | -9.619 | -17.36 | -20.11 | -38.52 | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -9.624 | -17.37 | -20.11 | -38.53 | -18.54 | -16.74 | -9.834 | -10.92 | -7.946 | -9.869 | -10.84 | -11.55 | -12.3 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.622 | -17.28 | -19.93 | -38.84 | -19.02 | -17.05 | -10.1 | -10.62 | -7.89 | -10.7 | -11.19 | -11.92 | -12.7 | - | - |
Net income 1 | -9.622 | -17.28 | -19.93 | -38.84 | -19.04 | -17.06 | -10.11 | -10.64 | -7.899 | -10.71 | -11.49 | -12.29 | -13.34 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4100 | -0.7400 | -0.8600 | -1.670 | -0.8200 | -0.7200 | -0.3700 | -0.2500 | -0.1900 | -0.2300 | -0.2267 | -0.2250 | -0.2400 | -0.2050 | -0.2150 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/3/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/9/23 | 5/15/23 | 8/3/23 | 11/2/23 | 3/6/24 | 5/2/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -30.2 | -85.6 | -56.2 | -42.2 | -62.8 | -89.4 |
ROE (net income / shareholders' equity) | - | -29.8% | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | -27.8% | - | - | - | - | - |
Assets 1 | - | 115.2 | - | - | - | - | - |
Book Value Per Share | - | 6.060 | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 21.5 | 21.6 | 21.6 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 6/4/21 | 3/3/22 | 3/9/23 | 3/6/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+572.25% | 197M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ELEV Stock
- Financials Elevation Oncology, Inc.